Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 17Observational 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × dacomitinib × Clear all
NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Pfizer

Completed
188 enrolled
Thoracic

Lung Neoplasms

NCT04609319 2025-05-31

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Pfizer

Completed
307 enrolled 25 charts
Thoracic

Lung Neoplasms

NCT04155541 2025-05-23

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Pfizer

Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Pfizer

Completed
5,279 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡